澳门威尼克斯人网站(中国 NO.1) - 百度百科

Cancer Primary Screening

DNA Methylation Detection Kit for Human PAX1, SOX1 and HAS1 Gene -- CERC (Cervical Cancer)

Clinical Application

World Health Organization aims to eradicate cervical cancer in the near future by expanding access to high-quality HPV screening and vaccination. It can be used as a complementary tool for cervical cancer screening, specific regions of methylation will be found in cervical exfoliated cells sample and provide a clinical reference for triage of primary HPV DNA-positive samples after primary screening.
Due to its high automation and more standardized procedures, it is likely to parallel or even replace cytology tests in the future.
 
  • More efficient, accurate and standardized HPV post-primary-screening traige method.
  • Assists in screening cervical cancer and diagnosing cervical lesions.
  • High diagnostic performance for cervical lesions and cervical cancer, and can be used as an auxiliary molecular marker for the early diagnosis of cervical lesions and cervical cancer.
  • Certain guiding significance for the treatment of cervical lesions and cervical cancer.
  • Significant clinical advantage on postmenopausal women sample compared with Cytology method.

Intended Use

This kit is a real-time PCR assay for qualitative detection of DNA methylation in gene PAX1, SOX1 and HAS1 in human genomic DNA extracted from cervical sample.

General Specification

Methodology: Real-Time PCR, PCR-Fluorescence Probing
Sample Type: Exfoliate Cervical Cell / LBC Specimen
Analytical Sensitivity: 88.21% (95% CI: 83.39% - 91.77%)
Analytical Specificity: 95.04% (95% CIL 90.11% - 96.58%)

Precision: CV <5%
LoD: 1% of PAX1, HAS1 and SOX1 methylation in the background of 5 ng human genomic DNA

Packing Specifications

24 tests/kit (non-single test/tube) 48 tests/kit (non-single test/tube)

Work Flow


Contact Us